arrow_back Back Filing freshness 10-Q Q2 FY2026 SEC EDGAR

Curaleaf Holdings, Inc.

CURLF
Price unavailable
Materials ·Medicinal Chemicals & Botanical Products ·USMedicinal Chemicals & Botanical Products
11 Visible periods
22 Metrics
Peer-ranked Benchmarks
Price Chart
30
Health
Poor
Bearish
auto_awesome

Analytical Summary

Curaleaf Holdings, Inc. faces fundamental challenges with weakness in Return on Common Equity (%) and Profit Margin (%). The fundamentals warrant careful consideration of downside risks.

Market Cap
Dividend Yield
Revenue Growth 9.5%
Op. Margin 1.2%
ROIC -0.1%
FCF / Share
Trailing P/E
Price / Book
FCF Yield
Debt / Equity 0.70
info Valuation on last close.

11-Year Financial Trajectory

Quarterly
Metric Value Trend Year over Year Percentile
Revenue Total top-line sales
$340.10M
↑ +9.5%
Net Income Profit after all expenses
$69.80M
↑ +214.3%
Operating Margin Operating profit as % of sales
1.2%
↓ -38.3% 33th
Long-Term Debt Long-term obligations
$611.54M
↑ +11.5%
trending_up

Bullish Indicators

  • No bullish signals detected.
warning

Bearish Risks

  • Profit Margin (%)Profit Margin (%) is in the bottom quartile
  • Return on Common Equity (%)Return on Common Equity (%) is in the bottom quartile

Health Breakdown

Profitability
31
Returns
23
Financial Health
45
Cash Quality
15

bar_chart Data from SEC EDGAR XBRL filings

Synced yesterday 7 years · 11 quarters